Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olpadronate
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Olpadronate is a bisphosphonate compound structurally and mechanistically related to alendronate and other drugs in this class. It acts primarily as an inhibitor of osteoclast-mediated bone resorption and is investigated for the treatment of conditions involving excessive bone turnover such as osteoporosis and Paget's disease. Its mechanism involves inhibition of key enzymes in the mevalonate pathway in osteoclasts, leading to decreased bone resorption. Olpadronate is not widely marketed in most countries and has primarily been investigated or used in select regions such as Argentina.
- Brand names
- Olpadron
- Other names
- olpadronate
02
Targets
FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on olpadronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olpadronate.